Pancreatic enzyme pharmacotherapy

Marcus Ferrone, Massimo Raimondo, James S. Scolapio

Research output: Contribution to journalReview article

62 Scopus citations

Abstract

Supplemental pancreatic enzyme preparations are provided to patients with conditions of pancreatic exocrine deficiency such as chronic pancreatitis and cystic fibrosis. These patients frequently experience steatorrhea, which occurs from inadequate fat absorption. The delivery of sufficient enzyme concentrations into the duodenal lumen simultaneously with meals can reduce nutrient malabsorption, improve the symptoms of steatorrhea, and in some cases alleviate the pain associated with chronic pancreatitis. Current clinical practices dictate administration of lipase 25,000-40,000 units/meal by using pH-sensitive pancrelipase microspheres, along with dosage increases, compliance checks, and differential diagnosis in cases of treatment failure. Despite the large number of specialty enzyme replacements available commercially, many patients remain dissatisfied with standard therapy, and future developments are needed to optimize treatment in these individuals.

Original languageEnglish (US)
Pages (from-to)910-920
Number of pages11
JournalPharmacotherapy
Volume27
Issue number6
DOIs
StatePublished - Jun 1 2007

Keywords

  • Cystic fibrosis
  • Pancreatic enzymes
  • Pancreatitis
  • Pancrelipase

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Pancreatic enzyme pharmacotherapy'. Together they form a unique fingerprint.

  • Cite this